Pyrimidine salvage in Toxoplasma gondii as a target for new treatment
Copyright © 2023 Elati, Goerner, Martorelli Di Genova, Sheiner and de Koning..
Toxoplasmosis is a common protozoan infection that can have severe outcomes in the immunocompromised and during pregnancy, but treatment options are limited. Recently, nucleotide metabolism has received much attention as a target for new antiprotozoal agents and here we focus on pyrimidine salvage by Toxoplasma gondii as a drug target. Whereas uptake of [3H]-cytidine and particularly [3H]-thymidine was at most marginal, [3H]-uracil and [3H]-uridine were readily taken up. Kinetic analysis of uridine uptake was consistent with a single transporter with a Km of 3.3 ± 0.8 µM, which was inhibited by uracil with high affinity (Ki = 1.15 ± 0.07 µM) but not by thymidine or 5-methyluridine, showing that the 5-Me group is incompatible with uptake by T. gondii. Conversely, [3H]-uracil transport displayed a Km of 2.05 ± 0.40 µM, not significantly different from the uracil Ki on uridine transport, and was inhibited by uridine with a Ki of 2.44 ± 0.59 µM, also not significantly different from the experimental uridine Km. The reciprocal, complete inhibition, displaying Hill slopes of approximately -1, strongly suggest that uridine and uracil share a single transporter with similarly high affinity for both, and we designate it uridine/uracil transporter 1 (TgUUT1). While TgUUT1 excludes 5-methyl substitutions, the smaller 5F substitution was tolerated, as 5F-uracil inhibited uptake of [3H]-uracil with a Ki of 6.80 ± 2.12 µM (P > 0.05 compared to uracil Km). Indeed, we found that 5F-Uridine, 5F-uracil and 5F,2'-deoxyuridine were all potent antimetabolites against T. gondii with EC50 values well below that of the current first line treatment, sulfadiazine. In vivo evaluation also showed that 5F-uracil and 5F,2'-deoxyuridine were similarly effective as sulfadiazine against acute toxoplasmosis. Our preliminary conclusion is that TgUUT1 mediates potential new anti-toxoplasmosis drugs with activity superior to the current treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in cellular and infection microbiology - 13(2023) vom: 20., Seite 1320160 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elati, Hamza A A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 23.02.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fcimb.2023.1320160 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366532146 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366532146 | ||
| 003 | DE-627 | ||
| 005 | 20240229144021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcimb.2023.1320160 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM366532146 | ||
| 035 | |a (NLM)38162577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Elati, Hamza A A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pyrimidine salvage in Toxoplasma gondii as a target for new treatment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elati, Goerner, Martorelli Di Genova, Sheiner and de Koning. | ||
| 520 | |a Toxoplasmosis is a common protozoan infection that can have severe outcomes in the immunocompromised and during pregnancy, but treatment options are limited. Recently, nucleotide metabolism has received much attention as a target for new antiprotozoal agents and here we focus on pyrimidine salvage by Toxoplasma gondii as a drug target. Whereas uptake of [3H]-cytidine and particularly [3H]-thymidine was at most marginal, [3H]-uracil and [3H]-uridine were readily taken up. Kinetic analysis of uridine uptake was consistent with a single transporter with a Km of 3.3 ± 0.8 µM, which was inhibited by uracil with high affinity (Ki = 1.15 ± 0.07 µM) but not by thymidine or 5-methyluridine, showing that the 5-Me group is incompatible with uptake by T. gondii. Conversely, [3H]-uracil transport displayed a Km of 2.05 ± 0.40 µM, not significantly different from the uracil Ki on uridine transport, and was inhibited by uridine with a Ki of 2.44 ± 0.59 µM, also not significantly different from the experimental uridine Km. The reciprocal, complete inhibition, displaying Hill slopes of approximately -1, strongly suggest that uridine and uracil share a single transporter with similarly high affinity for both, and we designate it uridine/uracil transporter 1 (TgUUT1). While TgUUT1 excludes 5-methyl substitutions, the smaller 5F substitution was tolerated, as 5F-uracil inhibited uptake of [3H]-uracil with a Ki of 6.80 ± 2.12 µM (P > 0.05 compared to uracil Km). Indeed, we found that 5F-Uridine, 5F-uracil and 5F,2'-deoxyuridine were all potent antimetabolites against T. gondii with EC50 values well below that of the current first line treatment, sulfadiazine. In vivo evaluation also showed that 5F-uracil and 5F,2'-deoxyuridine were similarly effective as sulfadiazine against acute toxoplasmosis. Our preliminary conclusion is that TgUUT1 mediates potential new anti-toxoplasmosis drugs with activity superior to the current treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 5-fluorodeoxyuridine | |
| 650 | 4 | |a 5-fluorouracil | |
| 650 | 4 | |a Toxoplasma gondi | |
| 650 | 4 | |a antimetabolite | |
| 650 | 4 | |a fluoropyrimidines | |
| 650 | 4 | |a pyrimidine salvage | |
| 650 | 4 | |a uracil transporter | |
| 650 | 4 | |a uridine transport | |
| 650 | 7 | |a Uracil |2 NLM | |
| 650 | 7 | |a 56HH86ZVCT |2 NLM | |
| 650 | 7 | |a Uridine |2 NLM | |
| 650 | 7 | |a WHI7HQ7H85 |2 NLM | |
| 650 | 7 | |a Thymidine |2 NLM | |
| 650 | 7 | |a VC2W18DGKR |2 NLM | |
| 650 | 7 | |a Membrane Transport Proteins |2 NLM | |
| 650 | 7 | |a Deoxyuridine |2 NLM | |
| 650 | 7 | |a W78I7AY22C |2 NLM | |
| 650 | 7 | |a Sulfadiazine |2 NLM | |
| 650 | 7 | |a 0N7609K889 |2 NLM | |
| 700 | 1 | |a Goerner, Amber L |e verfasserin |4 aut | |
| 700 | 1 | |a Martorelli Di Genova, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Sheiner, Lilach |e verfasserin |4 aut | |
| 700 | 1 | |a de Koning, Harry P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cellular and infection microbiology |d 2011 |g 13(2023) vom: 20., Seite 1320160 |w (DE-627)NLM220414289 |x 2235-2988 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g day:20 |g pages:1320160 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fcimb.2023.1320160 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |b 20 |h 1320160 | ||